Brand Name

Istodax

Generic Name
RomiDEPsin
View Brand Information
FDA approval date: January 04, 2010
Classification: Histone Deacetylase Inhibitor
Form: Injection, Kit

What is Istodax (RomiDEPsin)?

ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Who is this study for: Patients with relapsed or refractory peripheral T-cell lymphoma
Enrollment Status: Recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drugs: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine
Study Phase: Phase 2

Summary: The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidine to single agent drugs already determined effective in patients with PTCL. For the purposes of this study, the single a...

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Who is this study for: Adult patients with Peripheral T Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Pralatrexate, Romidepsin, Azacitidine
Study Phase: Phase 1/Phase 2

Summary: This is an open-label, Phase 1/2a, dose-finding study with an initial phase 1 portion, articulated in four separate treatment arms, followed by a dedicated phase 2 for qualifying treatment Arm(s). The primary objective of the Phase 1 portion is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of: Durvalumab, oral 5-azacitidine, and romidepsin (Arm ...

View All Clinical Trials

Related Latest Advances

Histone and non-histone protein acetylation in a tail regeneration model (Ambystoma mexicanum).
Histone and non-histone protein acetylation in a tail regeneration model (Ambystoma mexicanum).
Journal: Biology open
Published: June 01, 2026
Consensus transcriptional signature of dengue virus infection reveals coordinated interferon suppression and stress-response activation.
Consensus transcriptional signature of dengue virus infection reveals coordinated interferon suppression and stress-response activation.
Journal: Cell biochemistry and biophysics
Published: May 07, 2026
Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.
Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 31, 2026
View All Latest Advances